The Commission, on its own initiative, started the procedure under Article 8 of Regulation (EC) No 1925/2006 for monacolins in red yeast rice as it considered that on the basis of the available information that was provided by the Member States during a consultation on the safety of monacolins from red yeast rice, the necessary conditions and requirements laid down in Article 8 of that Regulation and Articles 3 and 4 of Commission Implementing Regulation (EU) No 307/2012 [Commission Implementing Regulation (EU) No 307/2012 of 11 April 2012 establishing implementing rules for the application of Article 8 of Regulation (EC) No 1925/2006 of the European Parliament and of the Council on the addition of vitamins and minerals and of certain other substances to foods (OJ L 102, 12.4.2012, p. 2).] were fulfilled. This available information included an opinion from the French Agency for Food, Environmental and Occupational Health & Safety (ANSES) on the risk associated with the presence of ‘red yeast rice’ in food supplements [ANSES Opinion Request No 2012-SA-0228: Opinion of the French Agency for Food, Environmental and Occupational Health & Safety on the risks associated with the presence of ‘red yeast rice’ in food supplements, 14 February 2014.]. That opinion concluded that ‘due to the composition of red yeast rice and in particular: the presence of monacolin K (also called lovastatin when marketed as a drug) that shares the adverse effects of statins; the presence at varying levels of the other monacolins, compounds whose safety has not been established, consumption of “red yeast rice” exposes some consumers to a health risk’. The available information also included a scientific advisory report adopted by the Belgian Superior Health Council on 13 February 2016 [Avis du Conseil Superieur de la Sante N° 9312 : Compléments alimentaires à base de «levure de riz rouge », 3.2.2016.] that provided an evaluation of the supposed beneficial effects and possible toxicity of dietary supplements based on red yeast rice for the Belgian population. That report referred to the risk associated with the presence of monacolins, in particular monacolin K, in red yeast rice that includes adverse effects identical to those observed in patients taking statin drugs and referred to a higher risk of developing toxic effects for certain vulnerable groups such as pregnant women, people suffering from liver, kidney and muscle disorders, persons aged over 70 years and children and adolescents. Another relevant scientific assessment was carried out by the German research funding organisation DFG in 2013 [Stellungnahme der Gemeinsamen Experten kommission BVL/BfArM: Einstufung von Rotschimmelreisprodukten, 8.2.2016.] that concluded that ‘red mould rice is not a safe food/food supplement’.
Recital 7, Regulation (EU) 2022/860
In forcesince 1 Jun 2022